RR
Rebala Rupakala
About Rebala Rupakala
Data last updated:
Rebala Rupakala is a Director at Hatri Pharma Private Limited (since 2017), Director at Emr Laboratories Private Limited (since 2016) and Director at Reddys Therapeutics Private Limited (since 2016). The companies operate in Pharma and Healthcare. The 3 current companies with reported revenue have a combined latest revenue of ₹89 Lakh; the largest is Hatri Pharma Private Limited at ₹71.7 Lakh (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 30 Oct 2017 | 2010 | ₹71.7 Lakh (FY 2025) | Active | |
| Director | 20 Oct 2016 | 2016 | ₹11.5 Lakh (FY 2023) | Active | |
| Director | 21 Oct 2016 | 2016 | ₹5.9 Lakh (FY 2022) | Active |
Board colleagues of Rebala Rupakala
| Name | DIN | Company | Designation |
|---|---|---|---|
| Mohan Reddy Enaganuri | 02720838 | Hatri Pharma Private Limited , Emr Laboratories Private Limited and 1 more | Director |
| Sumalatha Ambarapu | 10272329 | Hatri Pharma Private Limited | Director |
| Mohan Sai Sundar Reddy Devarapalli | 11007217 | Reddys Therapeutics Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Rebala Rupakala
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rebala Rupakala
Rebala Rupakala currently holds 3 directorships: Hatri Pharma Private Limited (Director, since 30 Oct 2017, revenue ₹71.7 Lakh (FY 2025)); Emr Laboratories Private Limited (Director, since 20 Oct 2016, revenue ₹11.5 Lakh (FY 2023)); Reddys Therapeutics Private Limited (Director, since 21 Oct 2016, revenue ₹5.9 Lakh (FY 2022)).
Rebala Rupakala was first appointed on 20 Oct 2016 as Director at Emr Laboratories Private Limited. The most recent appointment on record is 30 Oct 2017 at Hatri Pharma Private Limited.
The 3 current companies of Rebala Rupakala that report revenue have a combined latest revenue of ₹89 Lakh: Hatri Pharma Private Limited ₹71.7 Lakh (FY 2025); Emr Laboratories Private Limited ₹11.5 Lakh (FY 2023); Reddys Therapeutics Private Limited ₹5.9 Lakh (FY 2022).
The current boards of Rebala Rupakala's companies include Mohan Reddy Enaganuri (Hatri Pharma Private Limited), Sumalatha Ambarapu (Hatri Pharma Private Limited), Mohan Sai Sundar Reddy Devarapalli (Reddys Therapeutics Private Limited).